Core Insights - Vitarylon, a clinical-stage biotechnology company, focuses on developing transformative therapies for age-related diseases, has appointed two senior executives to enhance its research and development pipeline [2][6] Group 1: Executive Appointments - Nasir Khan, DVM, PhD, has been appointed as Senior Vice President of Preclinical Development effective October 20, 2025, bringing over 30 years of experience in drug safety evaluation and regulatory submissions [2][3] - Gary Ingenito, MD, PhD, will serve as Senior Vice President of Clinical Development starting November 1, 2025, with extensive experience in drug development across various therapeutic areas [2][4] Group 2: Company Strategy and Pipeline - The company aims to advance its R&D pipeline, which includes three clinical-stage projects and four promising molecules that could be first-in-class or best-in-class [2][6] - Vitarylon has a diverse project pipeline targeting key pathogenic mechanisms of age-related diseases, including dysregulated cell death and uncontrolled inflammation [6] Group 3: Leadership Experience - Nasir Khan has led the non-clinical safety evaluation of over 400 preclinical candidates and has been involved in the approval of 63 new drug applications, including notable drugs like Celebrex and Ibrance [3][4] - Gary Ingenito has over 30 years of experience in clinical research and regulatory affairs, having worked on drugs for various diseases, including neurodegenerative conditions [4][5]

Major Events - Zhonghui Biotech-B (02627) has its Huierkangxin® vaccine selected as the only vaccine in the preliminary list of innovative drugs for national medical insurance [1] - Stone Pharmaceutical Group (02005) has received approval from the National Medical Products Administration for the registration of Aminopyridine as an active pharmaceutical ingredient for marketed formulations [1] - Gilead Sciences-B (01672) reports that its obesity treatment candidate ASC47 shows better efficacy in preclinical models when combined with Teriparatide compared to Semaglutide [1] - GAC Group (02238) plans to increase investment of 600 million yuan in Huawang Automotive [1] - Tongguan Gold (00340) has been included in the MSCI Global Small Cap Index [1] Operating Performance - Tencent Holdings (00700) reported a net profit attributable to equity holders of 63.052 billion yuan for Q2, a year-on-year increase of 10% [1] - Cheung Kong Infrastructure Group (01038) announced a mid-year profit attributable to shareholders of 4.348 billion HKD, up 0.9% year-on-year [1] - Power Assets Holdings (00006) reported a mid-year profit attributable to shareholders of 3.042 billion HKD, an increase of 1.2% year-on-year [1] - Nexperia (01316) disclosed a mid-year profit attributable to equity holders of 63.48 million USD, a year-on-year increase of 304.46% [1] - Value Partners Group (00806) reported a mid-year profit attributable to shareholders of 252 million HKD, a significant increase of 572.7% year-on-year [1] - Samsonite (01910) announced a mid-year profit attributable to equity holders of 118 million USD, a year-on-year decrease of 30.2% [1] - Multi-Point Intelligence (02586) reported a mid-year profit attributable to shareholders of 67.526 million HKD, returning to profitability year-on-year [1] - Laika Pharmaceuticals-B (02105) has made significant clinical progress in its core pipeline in the first half of the year, with R&D expenses exceeding 100 million yuan [1] - China Metallurgical Group (01618) reported new contract signings of 611.34 billion yuan from January to July, a year-on-year decrease of 18.5% [1] - China Shenhua Energy (01088) reported coal sales of 24.27 million tons in the first seven months, a year-on-year decrease of 10.1% [1]

Core Viewpoint - The announcement highlights that Stone Four Pharmaceutical Group has received approval from the National Medical Products Administration of China for its Amaprine to be registered as an active pharmaceutical ingredient for use in marketed formulations, making it the first company in the country to achieve this [1] Company Summary - Stone Four Pharmaceutical Group's Amaprine is a potassium channel blocker primarily used to improve walking speed in adults with certain types of multiple sclerosis [1]

Core Viewpoint - The announcement indicates that Shijiazhuang Pharmaceutical Group has received approval from the National Medical Products Administration of China for its Amaprine to be used as an active pharmaceutical ingredient in marketed formulations, making it the first company in the country to achieve this approval [1] Group 1 - Shijiazhuang Pharmaceutical Group's Amaprine is a potassium channel blocker [1] - Amaprine is primarily used to improve walking speed in adults with certain types of multiple sclerosis [1]

Core Viewpoint - The company Shijiazhuang Fourth Pharmaceutical Group has received approval from the National Medical Products Administration of China for its active pharmaceutical ingredient, Amaprine, marking it as the first in the country to be approved for use in marketed formulations [1] Group 1 - Amaprine is a potassium channel blocker primarily used to improve walking speed in adults with certain types of multiple sclerosis [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 於本公告日期，董事局成員包括執行董事曲繼廣先生、蘇學軍先生、孟國先生、周興揚先生及 曲婉蓉女士，非執行董事劉文軍先生，以及獨立非執行董事王亦兵先生、周國偉先生及姜廣策 先生。 自願公告 產品開發的最新進展 石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 本集團的氨吡啶已獲中國國家藥品監督管理局批准登記成為在上市製劑使用的原料藥，是國內 首家獲批。氨吡啶是一種鉀通道阻滯劑，主要用於改善某些多發性硬化症成年人步行速度。 本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展情況。 承董事局命 執行董事兼公司秘書 周興揚 香港，二零二五年八月十三日 ...